Autoimmune Diseases  >>  glatiramer acetate  >>  Phase 3
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
glatiramer acetate / Generic mfg.
PreCISe, NCT00666224: Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome

Checkmark PRECISE
Apr 2013 - Apr 2013:  PRECISE
Checkmark Data
Oct 2010 - Oct 2010: Data
Checkmark Data
More
Completed
3
481
US, RoW
Glatiramer Acetate (DB), Copaxone®, Placebo, Glatiramer Acetate (OL)
Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
10/07
06/10
NCT00337779: Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

Completed
3
1155
US
Glatiramer Acetate (GA) 40 mg, Copaxone®, glatiramer acetate 20 mg
Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Remitting Multiple Sclerosis
10/08
10/08
Song, NCT00947752: Safety of New Formulation of Glatiramer Acetate

Completed
3
147
US
Glatiramer Acetate, F1, Experimental Glatiramer Acetate, F2
Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Remitting Multiple Sclerosis
09/09
11/09
ENCORE, NCT01167426: Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

Completed
3
148
US
Glatiramer Acetate 20 mg/0.5 mL, Copaxone®, Glatiramer acetate 20 mg/0.5 mL
Teva Neuroscience, Inc.
Multiple Sclerosis
11/10
12/10
NCT00429442 / 2006-001827-21: Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis

Withdrawn
3
0
Europe
Simvastatin, placebo
Anna Tsakiri, Sanofi
Relapsing Remitting Multiple Sclerosis
 
03/11
SURPASS, NCT01058005 / 2009-015556-15: Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

Checkmark Interim data
Oct 2010 - Oct 2010: Interim data
Terminated
3
84
US, Canada, Europe, RoW
BG00002 (natalizumab), Tysabri, interferon beta-1a, Rebif, glatiramer acetate, Copaxone
Biogen, Elan Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
04/12
04/12
NCT01578785 / 2011-005550-57: An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Terminated
3
178
US, Europe, RoW
Glatiramer Acetate, Copaxone®, Placebo
Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing-Remitting Multiple Sclerosis
10/12
11/12
NCT01874145: Safety and Tolerability of Glatiramer Acetate

Checkmark GLACIER
Sep 2014 - Sep 2014: GLACIER
Checkmark ACTRIMS-ECTRIMS 2014: MS (GLACIER)
Sep 2014 - Sep 2014: ACTRIMS-ECTRIMS 2014: MS (GLACIER)
Completed
3
209
US
GA 20 mg/mL, Glatiramer Acetate, Copaxone®, GA 40 mg/mL
Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing-Remitting Multiple Sclerosis
04/14
05/14
NCT01489254 / 2011-000888-27: Efficacy and Safety of GTR in Comparison to Copaxone®

Checkmark GATE trial
Oct 2015 - Oct 2015: GATE trial
Checkmark ECTRIMS 2015: Multiple sclerosis (GATE)
Sep 2015 - Sep 2015: ECTRIMS 2015: Multiple sclerosis (GATE)
Checkmark ACTRIMS-ECTRIMS 2014: MS (GATE)
More
Completed
3
794
US, Europe, RoW
Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo
Synthon BV
Multiple Sclerosis
01/15
01/15

Download Options